Takeda and Zinfandel write off yet another Alzheimer’s PhIII after Actos fails a key interim test
Hours after Eli Lilly spelled out exactly how bad its last batch of Phase III data for solanezumab was, Takeda stepped up to say …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
